News Summary: NVIDIA and Lilly bring together a world-leading, multidisciplinary team of scientists, AI researchers and engineers to address the hardest problems in drug discovery.The co-innovation lab infrastructure will be built on the NVIDIA BioNeMo platform and the NVIDIA Vera Rubin architecture.NVIDIA and Lilly will pioneer robotics and physical AI to accelerate and scale medicine discovery and production. SAN FRANCISCO, Jan. 12, 2026 (GLOBE NEWSWIRE) -- J.P. Morgan Healthcare Conference -- NVIDIA and ...

Core Insights - IBM Fusion has implemented one of the first NVIDIA AI Data Platform reference designs, enhancing AI-driven medical research capabilities at UT Southwestern Medical Center [1][2][4] Group 1: Technology Implementation - UT Southwestern Medical Center is the first client to deploy the NVIDIA AI Data Platform reference design with IBM Fusion, enabling large-scale training and inferencing for complex datasets [2][4] - The NVIDIA AI Data Platform integrates enterprise storage with accelerated computing, allowing for near-real-time business insights and AI-ready data processing [3][4] Group 2: Research Applications - IBM Fusion supports various deep research use cases, including drug discovery acceleration and clinical training, by unifying applications and data access across hybrid clouds [5][6] - The platform enables the creation of AI-driven patient avatars for simulating clinical scenarios, enhancing the training environment for medical students [6] Group 3: Strategic Partnerships - IBM's collaboration with NVIDIA aims to unlock hidden insights from data, enhancing AI and analytics initiatives in healthcare research [5][6] - The integration of NVIDIA BioNeMo framework with IBM Fusion allows researchers to build and train deep learning models for biomolecular discovery [6]

Core Viewpoint - NVIDIA collaborates with Novo Nordisk to enhance drug discovery through advanced AI technologies, utilizing the Gefion supercomputer for innovative research and development applications [1][3][13] Group 1: Collaboration and Technology - The partnership aims to create customized AI models for early research and clinical development, leveraging advanced simulation and physical AI technologies [2] - Gefion, powered by NVIDIA DGX SuperPOD™, serves as an AI factory for Novo Nordisk, enabling the execution of drug discovery and agentic AI workloads [3][5] - NVIDIA's tools, including BioNeMo™, NIM™, and NeMo™, will facilitate generative AI-powered drug discovery and the development of customized workflows [3] Group 2: Research Focus - Novo Nordisk researchers will utilize single-cell models to predict cellular responses to drug candidates and design models for drug-like molecules [4] - The collaboration will also focus on building biomedical large language models from Novo Nordisk's extensive scientific literature to identify correlations between genes, proteins, and diseases [4] Group 3: Impact on Healthcare - Gefion's computational power is expected to address significant R&D challenges, aiming to unlock new possibilities in pharmaceutical research and development [6] - Danish startup Teton is using Gefion to develop an AI care companion for hospitals, which has shown a 25% reduction in nightshift duties for nurses [7] - Gefion will support efforts to unify health data across Danish health organizations, facilitating secure access to interconnected health data for research [9]